Skip to main content

Table 4 Comparison of Endostar with PBDC versus PBDC alone by different stratifications

From: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

Item Wang JW 2005[11] Yang L 2005[12]
  Group 1 N (%) Group 2 N (%) P-value Group 1 N (%) Group 2 N (%) P-value
Sex       
Male 74 (32.3) 19 (16.2) 0.001 - - -
Female 40 (43.0) 13 (27.7) 0.08 - - -
Histology       
SCC 49 (38.0) 10 (18.2) 0.009 11 (47.8) 3 (30) 0.476
LAC 54 (32.7) 17 (17.3) 0.007 6 (22.2) 5 (21.7) 1.000
Others 11 (39.3) 5 (45.5) 0.72    
TNM stage       
IIIA 17 (33.3) 5 (16.7) 0.11 10 (52.6) 3 (23.1) 0.147
IIIB 29 (33.7) 10 (22.2) 0.17
IV 68 (36.8) 17 (19.1) 0.003 9 (25.7) 5 (25) 1.000
Treatment history       
No 92 (40.0) 28 (23.9) 0.003 10 (37) 4 (19) 0.214
Yes 22 (23.9) 4 (8.5) 0.034 10 (37) 4 (33.3) 1.000
  1. Group 1, Endostar combined with PBDC; Group 2. PBDC alone; LAC, lung adenocarcinoma; SCC, squamous cell carcinoma.